Search results
Is CRISPR Therapeutics Stock a Buy? | The Motley Fool
The Motley Fool· 11 hours agoCRISPR Therapeutics (CRSP 0.99%) is a star in the gene-editing therapy niche. The company made...
BLUE vs. CRSP: Why Are These Stocks Moving in Opposite Directions?
TipRanks via Yahoo Finance· 5 hours agoLast week, Bluebird Bio (NASDAQ:BLUE) shares climbed while CRISPR Therapeutics (NASDAQ:CRSP) stock...
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
Zacks via Yahoo Finance· 4 days agoRecently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes...
Is CRISPR Stock Going to $95? 1 Wall Street Analyst Thinks So. | The Motley Fool
The Motley Fool· 2 days agoCRISPR Therapeutics (CRSP 2.24%) closed last week down 8.5% after reporting first-quarter "earnings"...
CRISPR Therapeutics AG [CRSP] Records 200-Day SMA of $59.40 – Knox Daily
Knox Daily· 17 hours agoInvestors can speculate about the future of a stock by watching how its insiders buy and sell stocks. CRISPR Therapeutics AG shares valued at $1,173,232 were sold by Kulkarni ...
CRISPR can treat common form of inherited blindness, early data hint
Live Science via Yahoo News· 2 days agoA photo shows two male doctors in surgery garb as one preps a long needle for a procedure. A patient...
Gene Editing Breakthrough: CRISPR Improves Vision in Clinical Trial
SciTechDaily· 4 days agoMass Eye and Ear researchers say their findings support continued research and clinical trials of ...
CRISPR Therapeutics’ (CRSP) Neutral Rating Reiterated at Cantor Fitzgerald
ETF DAILY NEWS· 5 days agoCantor Fitzgerald reissued their neutral rating on shares of CRISPR Therapeutics (NASDAQ:CRSP – Free Report) in a research note issued to investors on Thursday, Benzinga reports ...
Broker Revenue Forecasts For CRISPR Therapeutics AG (NASDAQ:CRSP) Are Surging Higher
Simply Wall St. via Yahoo Finance· 6 days agoCRISPR Therapeutics AG (NASDAQ:CRSP) shareholders will have a reason to smile today, with the...
How Gene Editing Therapies Could Go Beyond Rare Diseases
Forbes· 2 days agoEarlier this year, a group of scientists in the Netherlands used the gene editing tool CRISPR to...